REVIEW U.S. FDA / CGMP GUIDELINES WITH FOCUS ON CO 2016 - Avoid Warning Letters in View of the U.S. FDA's Stated Goal - By AtoZ Compliance

Website https://www.atozcompliance.com/trainings-webinar/life-sciences/fda-compliance/life-science-industry- | Edit Freely

Category Education; E-Learning

Deadline: July 19, 2016 | Date: July 19, 2016

Venue/Country: online webinar, U.S.A

Updated: 2016-06-22 21:29:43 (GMT+9)

Call For Papers - CFP

Learn how to minimize the chance of receiving an FDA Warning Letter, what to doing during and after an FDA compliance audit to avoid common areas for critical mistakes.

Overview:

FDA Warning Letters and recent high-profile recalls indicate major cGMP training deficiencies in many companies.

Why Should You Attend:

Targeted cGMP issues. How can a company proactively minimize the chance of receiving a Warning Letter? Areas a company "must review" beforehand. What to doing during an FDA compliance audit training?

What to do immediately after the audit? What to do during the response period. Lessons learned.

Areas Covered In This Webinar:

The U.S. FDA's new aggressive implementation plans

Proactive reviews of the applicable U.S. FDA / cGMP guidelines

Key areas to focus limited resources

Learning Objectives:

FDA Inspectional objectives

Common areas for critical mistakes

Recent trends and events

The compliance audit

Who Will Benefit:

Senior Management

Project Leaders

Regulatory Affairs

Quality Systems Personnel

Internal and Supplier Auditor Personnel

R&D and Engineering Staff

CAPA and P&PC Personnel

For more information, please visit : https://www.atozcompliance.com/trainings-webinar/life-sciences/fda-compliance/life-science-industry-fda-compliance-avoid-warning-letters-in-view-of-the-us-fda/john-e-lincoln/300052

Email: supportatozcompliance.com

Toll Free: +1- 844-414-1400

Tel: +1-516-900-5509

Level:

Beginner

Speakers Profile:

John E. Lincoln

John E. Lincoln, is Principal of J. E. Lincoln and Associates LLC, a consulting company with over 33 years' experience in U.S. FDA regulated industries, 19 of which are as an independent consultant. John has worked with companies from start-up to Fortune 100, in the U.S., Mexico, Canada, France, Germany, Sweden, China and Taiwan. He specializes in quality assurance, regulatory affairs, QMS problem remediation and FDA responses, new / changed product 510(k)s, process / product / equipment including QMS and software validations, ISO 14971 product risk management files / reports, Design Control / Design History Files, Technical Files. He's held positions in Manufacturing Engineering, QA, QAE, Regulatory Affairs, to the level of Director and VP (R&D).

In addition, John has prior experience in military, government, electronics, and aerospace. He has published numerous articles in peer reviewed journals, conducted workshops and webinars worldwide on CAPA, 510(k)s, risk analysis / management, FDA / GMP audits, validation, root cause analysis, and others. He writes a recurring column for the Journal of Validation Technology. John is a graduate of UCLA.